Shearman & Sterling represented Boston Scientific in a definitive agreement to acquire Axonics Inc., a publicly traded medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction, for a cash price of $71 per share, reflecting an equity value of approximately $3.7 billion. The transaction was announced on Jan. 8, 2024 in a press release.
Boston Scientific, a global medical technology leader for more than 40 years, expects to complete the transaction in the first half of 2024, subject to customary closing conditions.
The Team
Practices
Industries
Regional Experience